Amiloidose primária Perspectiva terapêutica

Autores

  • Francisco Parente Assistente Hospitalar de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Diniz Vieira Assistente Graduado de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Paula Pimenta Assistente Hospitalar de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Borges Alexandrino Assistente Graduado de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Políbio Serra e Silva Director do Serviço de Medicina II dos Hospitais da Universidade de Coimbra e Professor Catedrático da Faculdade de Medicina

Palavras-chave:

amiloidose primária, terapêutica, alfa-interferão

Resumo

Os autores realçam as dificuldades de encontrar na terapêutica da amiloidose primária, quer pelos resultados obtidos, quer pela sua avaliação. Revêm os diferentes esquemas utilizados tecendo ainda considerações a propósito das implicações na terapêutica das disfunções dos múltiplos orgãos envolvidos. Por fim, apresentam a proposta de inclusão do alfa-interferão na terapêutica desta entidade.

Downloads

Não há dados estatísticos.

Referências

Levy Y. Belghiti-Deez D, Sobel A. Traitement de l'amylose sans myeloma Ann Med lntern 1988;139(3):190-193.

Gertz M. Kyle R. Response of primary hepatic amyloidosis to mel­phalan and prednisone: a case report and review of the litera­ture. Mayo Clin Proc 1986; 61: 218 - 223.

Kyle R. Greipp P, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blo­od 1986: 68(1) 220-224.

Gertz M, Kyle R. Primary systemic amyloidosis - a diagnostic pri­mer. Mayo Clin Proc 1989; 64:1505-1519.

Greipp P. Amyloidosis (AL), an approach to early diagnosis. Arch Intern Med 1984; 2144:2145.

KyleR. Greipp P. Primary systemic amyloidosis: comparision of melpha­lan and prednisone versus placebo. Blood 1978; 52(4): 818-827.

Stone M. Amyloidosis: a final common pathway for the protein deposition in tissues. Blood 1990;75(3):531-545.

Gertz M. Kyle R. Phase II triai of alpha-tocoferol (vitamin E) in the treatment of primary systemic amyloidosis. Amj Haemat 1990; 34 ( 1): 55-58.

Cohen H. Lessin L, Burkholder P. Resolution of primary amyloi­ dosis during chemotherapy, studies in a patient with nephro­ tic syndrome. Ann lntem Med 1975; 82: 466-473.

Fielder K. Durie B. Primary amyloidosis associated with multiple myeloma: predictors of sucessfull therapy. Am J Med 1986; 80: 413-418.

Schaltner A. Varon D, Green L, Hurvitz N, Bentwitch Z. Primary amyloidosis with unusual bone involvement reversibility with melphalan, prednisone and colchicine. Am J Med 1989; 86: 347-348

Schwartz R, Cohen], Schrier L. Theraphy of primary amyloidosis with melphalan and prednisone. Arch Intern Med 1979; 139:1144-1147.

l3. Kyle R, Greipp P. GartonJ, Gertz M. Primary systemic amyloido­sis: comparision of melphalan/prednisone versus colchicine. Am J Med 1985; 79:708-718

Kyle R, Wagoner R, Holley K. Primary systernic amyloidosis, resolution of nephrotic syndrome with melphalan and predni­sone. Arch Intem Med 1982; 142: 1445-1447.

Galton DA, Babapulle FB. The management of myelomatosis. EurJ Haematol 1987; 39:385- 398.

Gertz NI, Kyle R. Successful treatment of primary amyloidosis Oetter). The authors reply. Mayo Clin Proc 1986; 61: 835-836.

Hawkins P, Lavender P, Pepys M. Evaluation of systemic amyloi­ dosis by scintigraphy with 123-1-labeled serum amyloid P com­ponent. New Engl J Med 1990; 323: 508-513.

Fritz D, Luggen M, Hess E. Unusual longevity in a prymary syste­mic amyloidosis: a 19 year survivor. Am J Med 1989; 86: 245-248.

Cohen A. Amyloidosis, in Harrison's Principies of internal Medi­cine, New York, McGraw- Hill, 12.ª ed, 1991: 1417-1421.

Kyle R. Primary systemic amyloidosis. J Intern Med 1992: 232( 6): 523-524.

Alexanian R, Bagsagel D, Migliore P, Vaughn W, Howe C. Mel­ phalan thelapy for plasma cell myeloma Blood 1968: 31(1); 1-10.

Getz M, Kyle R. Acute leukemia and cytogenetics abnormalities complicating melphalan treatment of primary systemic amyloi­ dosis. Arch Intem Med 1990; 150: 629-633.

Wolf B, Kumar A, Vera J, Neiman R. Bone marrow morphology and immunologyin systemic amyloidosis. Am J Clin Pathol 1986; 86: 84-88.

Buxbaum J, Hurley M, Chuba J, Spiro T. Amyloidosis of the AL type: clinical, morphologic and biochemical aspects of the therapy with alkylating agents and prednisone. AmJ Med 1979: 67: 867-878.

Buxbaum J. Aberrant imunoglobulin synthesis in light chain amyloidosis. J Clin Invest 1986; 78:798-806.

Alexanian R, Haut A, Khan A, Lane M, Mckelvey E. Migliore P. Stuckey W, Wilson H. Treatment for mtiltiple myeloma, com­bination chemotherapy with different melphalan dose regi­ments. JAMA 1969; 208(9): 1680-1685.

Benson M. Treatment of AL amyloidosis with melphalan, preel­nisone, and colchicine. Arritis Rheum 1986; 29(5):683-687

Waziéres B, Fest T, Humbert P, Vuitton D, Duponel J. Amylose familiale de type AL et déficit en facteur X, intérêt de la colchi­cine au long cours. Ann Med lntem 1990; 141(4):388-340.

Manoharan A. Successful treatment of primary amyloidosis Letter). Mayo Clin Proc 1986; 61:835.

Corkery J, Bem MM, Tullis JL. Resolution of amyloielosis and plas­ma cell elyscrasia with combination chemotherapy (letter). Lancet 1978; 2: 425-426.

McMillan R, Longmire R. Yelenosky R: The effect of corticoste­roids on human IgG synthesis. J lmmunol 1976:116 (6): 1592-1595.

Kanoh T. Fatal paralyticus ileus following vinelesine chemothe­rapy in a patient with myeloma associated amyloidosis. Eur J Haematol 1989: 42(1): 108.

Solomom A, McLaughlin C, Capra J. Bence Jones proteins and light chains of immunoglobulins. XL A transient bence jones­ related protein associated with corticosteroiel therapy. J Clin Invest 1975; 55: 579-586.

Kanoh T, Nakamura Y, Kawai C. Enhancement of amyloielosis by high-dose pednisolone therapy in multiple myeloma Eur J Haematol 1989; 43 (1 ): 83.

Jones NF, Hilton PJ, Tighe JR, Hobbs JR. Treatment of primary amyloidosis with melphalan. Lancet 1972; 23 Set: 616-619.

Sheehan-Dare R, Simmons A. Amyloid myopathy and myeloma response to treatment. Postgrad Med J 1987; 63:141-142.

Camonano J, Greipp P, Bayer G, Bowie W. Resolution of adqui­red factor X deficiency and amyloidosis with melphalan and prednisone therapy. New Engl J Med 1987; 316(18):1133-1134.

Nores J, Dalayeun J, Remy J, Nenna A. Évolution sur douze ans d'un plasmocytome multicentrique non excrétant avec amylo­se. Ann Med Intern 1987; 138(8):679-680.

Michael J, Jones N. Spontaneous remissions of nephrotic syn­drome in renal amyloidosis BMJ 1978;1:1592-1593.

Dewald G, Kyle R, Hicks G, Greipp P. Toe clinical significance of cytogenetic studies in 100 patients with multipie myeloma, plas­ma cell leukemia or amyloidosi. Blood 1985; 66: 466-473.

Majolino I, Marceno R, Pecoraro G, Scime R, Vasta S, Liberti G, Rizzo A, Indovina A, Caronia F. High-dose therapy and auto­ logous transplantation in amyloidosis-AL. Haemat 1993; 78(1): 68- 71.

Barlogie B, Smith L, Alexanian R. Efective treatment of advanced multiple myeloma refractory to alkylanting agents. New England J Med 1984; 310(21):1354-1356.

Samson D, NewlandA, Keamey J,Joyner M, Mitchell T, BarettA, Gaminara E, Van Pette J, McCarthy D, Aston L, Hamon M, Evans

M. Infusion of vincristine and doxorubicin with oral dexame­ thasone as first-line therapy for multiple myeloma. Lancet 1989; 14 Oct: 882-885.

Elezovic L Djukanovic R, Rolovic Z. Sucessful treatment of he­ morragic syndrome dueto anadquired, combined deficiency of factores Vll and X in a patient with multiple myeloma and amyloidosis. Eur J Hemat 1989; 42(1): 105-106.

Editorial: Colchicine in amyloidosis. Lancet 1986; 2(8509): 724-725.

Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gaíni J. Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever. New EnglJ Med 1986; 314:1001-1005.

Cohen A, Rubinow A, Anderson J, Skinner M, MasonJ, Libbey C, Kayne H: Survival of patients with primary (AL) amyloidosis: colchicine treated cases from 1976 to 1983 compared with cases seen in previow years (1961 to 1973). Am J Med 1987; 82: 1182-1190.

Durie B, Perksy B, Scoehnlen B, Grogan T, Salmon S. Amyloid production in human myeloma stem-cell culture, with mor­phologic evidence of amyloid secretion by associated macro­ phages. New Eng!J Med 1982;307(27):1688-1692.

Glenner G. Amyloid deposits and amyloidosis. The b-fibrilloses. New Engl J Med 1980; 302(24):1333-1341.

Goodmann & Gilman. The Pharmacological basis of therapheu­ tics. 8.ª ed, Ed. Pergamon Press, 1991.

Rijwijk, Donker J, Ruinen L. Dimethylsulfoxide in amyloidosis. Lancet 1979;27Jan: 207-208.

Tonokunaka S, Osanai H, Morikawa M, Yachiku S. Experience with dimethylsulfoxide treatment for primary localizated amyloidosis of the bladder. J Urol 1986; 135:580-582.

Iwasaki T, Hamano T, Aizawa K, Kobayaski K, Kasishita E. A case of pulmonary amyloidosis associated with multiple mye­loma successfully treated with dimethyl sulfoxide. Acta Hae­matol 1994; 91 (2): 91-94.

Ravid M, Chen B, Bernheim J, Kedar 1. Ascorbic acid-induced regression of amyloidosis in experimental animais. J Exp Path 1985; 66:137-141.

Leinonen H, Sintonen SP. Cardiac amyloidosis, therapeutic and diagnostic difficulties with reference to two different forms of the disease. Acta Med Scand 1986; 219:125-128.

Bouhour JB, Haddalc M, Lefevre M. Le risque des bêta-bloqueurs et des inhibiteurs calciques dans la cardiopathie amyloide Presse Medicale 1986;15(21): 981.

Pollak A, Falk R. Left ventricular systolic dysfunction precipita­ted by verapamil in cardiac amyloidosis. Chest 1993;104(2): 616-620.

Greipp P, Kyle R, Bowie W. Factor X deficiency in primary amyloi­dosis New Engl Med 1979; 301(19):1050-1051.

Rosenstin E, Itzkowitz S, Penziner A, Cohen J, Mornaghi: Resolu­tion of faclor X deficency in primary amyloidosis following splenectomy. Arch Intem Med 1983; 143 597-599

Levin M, Chokas W. Adquired factor X deficiency and amyloido­sis treated with melphalan and prednisone. New Engl J Med 1987;317(18): 1155-1156.

Goldstein D, Laszio J. Interferon therapy in cancer from imagi­non to interferon. Cancer Res 1986;46:4315-4329.

Roth M, Foon K. Alpha interferon in the treatment of hematolo­gic malignancies. AmJ Med 1986; 81: 871-882.

Bergsagel G. Haas R, Messner A. lnterferon 2-b in the treatment of chronic ganulocytic leukemia, Semin Oncol 1986; 13 (Supl 2) 29-34.

Breenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in asemisolid agar culture system. Scand J Haematol 1985; 35: 178-185.

Breenning G. Ahre A, Nilsson K: Correlation betwveen in vitro and in vivo sensitivity to human leucocyte alpha-interferon in patients with multiple myeloma. ScandJ Haematol 1985; 35: 543-549.

Mandelli F, Avvisali G, Amadori S, Boccadoro M, Gernone A, Lauta V, Marmont F, Tribailo M, Dammaco F, Pilezi A: Mainte­nance treatment with recombinant interferon alpha-2b in pa­tients with multiple myeloma responding to conventional in­ duction chemotherapy. New Engln J Med 1990; 322:1430-1434.

Castanzi J, Cooper R, Scarffe J, Ozer H, Grubbs S, Ferraresi R, Pollard R, Spiegel R: Phase II study of recombinant alpha-in­terferon in resistent multiple myeloma. J Clin Oncol 1985; 3: 654- 659.

Durie B. Chemotherapy of multiple myeloma. Clin Haematol 1991; 4(1): 181-195.

Montuoro A, De Rosa L, De Blasio A, Pacilli L Petti N. Alpha-2.ª interferon/melphalan/prednisone versus melphalan/predni­sone in previously unteated patients with multipie myeloma. Br J Haematol 1990; 76:365-368.

Tanaka H, Tanabe O, lwato K, Asaoku H, lshikawa H, Nobuyoshi M, Kawano M, Kuramoto A: Sensitive inhibitory effect of in­terferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74(5): 1718-1722.

QuesadaJ, Alexanian R, Hawkins M, Barlogie B, Borden E, ltri L, Gutterman J. Treatment of multiple myeloma with recombi­nant alpha-interferon. Blood 1986; 67(2):275-278.

Ehersson H, Eksborg S, Wallin I, Ostreborg A, Mellstedt H. Oral melphalan pharmacokinetics: influence of interferon-induced fever. Clin Pharmacol Ther 1990, 47:86-90.

Parente F, Lopes S, Silva JM, Goncalves L, Mota O, Costa A, Lourenço A, Alexandrino B, Silva PS: Amiloidose Primária - experiência do Serviço de Medicina II dos HUC. Livro de re­sumos das II Jornadas de Medicina Interna da Zona Sul, 1990.

Parente F, Gonçalves L, Lopes S, Fernandes A, SilvaJM, Simões A, Aleandrino B, Silva PS. A propósito de um caso de amiloi­dose primária. Arq Med 1993; 7(2): 121-125.

Becherel PA, Boisnic S, Paul C, FermandJP, Frances C. Amylose diffuse: presentation buccale inhabituelle et tentative thera­peutique par interferon alpha. Ann Dermatol Venereol 1993; 120 (11): 799-801.

Gertz MA, Kyle R. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hae­matol 1993 Oct; 44(2): 125-128.

Ficheiros Adicionais

Publicado

30-06-1995

Como Citar

1.
Parente F, Vieira D, Pimenta P, Alexandrino B, Serra e Silva P. Amiloidose primária Perspectiva terapêutica. RPMI [Internet]. 30 de Junho de 1995 [citado 13 de Junho de 2024];2(2):97-105. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/2378

Edição

Secção

Artigos de Revisão

Artigos mais lidos do(s) mesmo(s) autor(es)

1 2 3 4 > >>